1.Pathogenesis Evolution and Prevention-treatment Strategies for Hypertension-related Coronary Microvascular Dysfunction Based on Collateral Disease Theory
Mingyan HUANG ; Linzi LONG ; Xin LIU ; Chao LIU ; Lifang SONG ; Changgeng FU ; Jiahui QIN ; Jieming LU ; Yi LI
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(23):239-248
This article explores the pathogenesis , evolution and the prevention-treatment strategies of hypertension-related coronary microvascular dysfunction (H-CMD) from the collateral disease theory. Long-term hypertension may lead to coronary microvascular vasomotor imbalance, endothelial injury, vascular remodeling, microthrombosis, reduced perfusion reserve, and microvascular rarefaction, suggesting a progressive pathological process from functional disturbance to structural injury, collateral obstruction, and insufficient repair. Collateral disease theory emphasizes the network-like distribution, gradual branching, and permeating and nourishing functions of collaterals, as well as the concept that prolonged disease enters the collaterals, providing a reference for understanding coronary microcirculatory dysfunction and malnourishment of heart collaterals. Accordingly, the traditional Chinese medicine (TCM) pathogenesis of H-CMD can be summarized into four interconnected stages: Collateral Qi stagnation, scorching injury of collateral vessels, phlegm-stasis obstruction of collaterals, and collateral deficiency with malnourishment. Collateral Qi stagnation is the initiating stage, mainly corresponding to abnormal coronary microvascular vasomotor regulation and endothelial dysfunction. Scorching injury of collateral vessels represents the developmental stage and is closely associated with inflammation, oxidative stress, and endothelial barrier injury after Qi stagnation transforms into fire. Phlegm-stasis obstruction of collaterals represents the prolonged stage and may aggravate vascular wall thickening, luminal stenosis, microthrombosis, and insufficient microcirculatory perfusion. Collateral deficiency with malnourishment is the late-stage outcome, reflecting deficiency of healthy Qi, collateral damage, Qi-blood malnourishment, and weakened repair capacity, mainly manifested as microvascular rarefaction, occlusion, and microcirculatory homeostatic imbalance. Therapeutically, stage-based syndrome differentiation and the combined strategy of dredging and nourishing collaterals should be emphasized. Specifically, promoting Qi movement, resolving stagnation, soothing the liver, and harmonizing collaterals should be adopted in the early stage. Clearing heat, pacifying the liver, calming and protecting collaterals should be adopted in the developmental stage. Resolving phlegm, activating blood, and dredging collaterals should be implemented in the prolonged stage. Supplementing Qi, nourishing blood, tonifying the kidney, regulating balance, strengthening healthy Qi, and nourishing collaterals should be carried out in the late stage. Related formulas and medicinals may act by regulating the nitric oxide/endothelin-1(NO/ET-1) balance, inhibiting inflammation and oxidative stress, improving microcirculatory perfusion, and promoting angiogenesis and endothelial repair. Collateral disease theory may provide a theoretical basis for understanding the dynamic pathogenesis of H-CMD and for stage-based TCM intervention.
2.Empowering Clinical Trial Project Management Through Low-Code Technology
Hao XIN ; Long YUAN ; Chunkai LI ; Zhidan WANG ; Zhichen ZHAO ; Yu LIANG ; Mingyan JIANG ; Yuanguo XIONG ; Yingkai WANG ; Feng WANG ; Jianhua CAO ; Hui LI
Herald of Medicine 2025;44(10):1688-1696
Objective To addresses the challenges arising from the rapid expansion of pharmaceutical clinical trials and the growing demands for quality management,this paper investigates the application of low-code technology in project management.Its goals are to enhance the operational efficiency and execution capabilities of clinical trial institutions,ensure trial quality and safety,and accelerate the translation of pharmaceutical scientific achievements.Methods A brainstorming session was conducted to analyze the technical and functional requirements for managing pharmaceutical clinical trial projects.Utilizing the "template design" and "decision analysis" functionalities of low-code technology,the study adopted a modular and visually driven data management approach to develop a system compliant with Good Clinical Practice(GCP)standards.This system integrates key functionalities,including project progress management,funding management,drug inventory management,and quality control.Its effectiveness was evaluated through real-world operation and performance validation.Results The system had demonstrated stable operation with substantial improvements in practical application.Compared with conventional management approaches,it significantly enhanced project management efficiency:the time required for project schedule management was reduced by 80%,the efficiency of financial processing increased by 95%,drug inventory management efficiency improved by 75%,and the time spent on quality control was shortened by 60%.Conclusion The pharmaceutical clinical trial project management system developed using low-code technology offers substantial advantages and promising application potential.It represents a critical practice in applying digital and intelligent tools to advance pharmaceutical productivity in the medical and healthcare sectors.
3.Empowering Clinical Trial Project Management Through Low-Code Technology
Hao XIN ; Long YUAN ; Chunkai LI ; Zhidan WANG ; Zhichen ZHAO ; Yu LIANG ; Mingyan JIANG ; Yuanguo XIONG ; Yingkai WANG ; Feng WANG ; Jianhua CAO ; Hui LI
Herald of Medicine 2025;44(10):1688-1696
Objective To addresses the challenges arising from the rapid expansion of pharmaceutical clinical trials and the growing demands for quality management,this paper investigates the application of low-code technology in project management.Its goals are to enhance the operational efficiency and execution capabilities of clinical trial institutions,ensure trial quality and safety,and accelerate the translation of pharmaceutical scientific achievements.Methods A brainstorming session was conducted to analyze the technical and functional requirements for managing pharmaceutical clinical trial projects.Utilizing the "template design" and "decision analysis" functionalities of low-code technology,the study adopted a modular and visually driven data management approach to develop a system compliant with Good Clinical Practice(GCP)standards.This system integrates key functionalities,including project progress management,funding management,drug inventory management,and quality control.Its effectiveness was evaluated through real-world operation and performance validation.Results The system had demonstrated stable operation with substantial improvements in practical application.Compared with conventional management approaches,it significantly enhanced project management efficiency:the time required for project schedule management was reduced by 80%,the efficiency of financial processing increased by 95%,drug inventory management efficiency improved by 75%,and the time spent on quality control was shortened by 60%.Conclusion The pharmaceutical clinical trial project management system developed using low-code technology offers substantial advantages and promising application potential.It represents a critical practice in applying digital and intelligent tools to advance pharmaceutical productivity in the medical and healthcare sectors.
4.Effect of GIV on neuroinflammatory response in a model of cerebral ischemia/reperfusion inj ury
Ming Chen ; Peng Shi ; Mingyan Xia ; Tingting Long ; Wenfeng Yu
Acta Universitatis Medicinalis Anhui 2023;58(1):54-59
Objective:
To investigate whether GIV , a coiled helix structural domain protein containing 88A , has an effect on the neuroinflammatory response in a model of cerebral ischemia⁃reperfusion injury.
Methods:
A middle cerebral artery embolization⁃reperfusion model (MACO/R) and an oxygen glucose deprivation/reoxygenation model ( OGD 6 h + R 24 h) of BV2 microglia were constructed in C57BL/6 mice , and the area of cerebral infarction was detected by TTC staining; the Longa neurobiological score was used to evaluate the degree of neurological deficit in mice ; ELISA was used to detect the release of IL⁃6 and TNF⁃α in the supernatant of peripheral blood and cell cultures , and Western blot was used to detect the protein expression of GIV , TREM2 and TLR4 in the cortical area around the infarct foci in mice ; different concentrations of lipopolysaccharide (LPS , 1 , 5 , 10 μg/ml) were used to stimulate BV2 cells for 24 h to establish a neuroinflammation model , qRT⁃PCR was performed to detect the mRNA levels of IL⁃6 , TNF⁃α and IL⁃1β , and Western blot was used to detect the expression of GIV ; OGD/R culture treatment was performed after knocking down the expression of GIV gene using siRNA interference technique ;ELISA was performed to detect the release concentration of IL⁃6 and TNF⁃α in cell culture medium supernatant;protein immunoblotting was performed to detect the knockdown efficiency of GIV.
Results :
Both the successfully constructed MCAO/R and OGD/R models activated the neuroinflammatory response and induced a decrease in protein expression of GIV ; MCAO/R induced increased concentrations of IL⁃6 and TNF⁃α release in peripheral blood of mice and promoted the protein expression of TREM2 and TLR4 ; LPS activated IL⁃6 , IL⁃1β and TNF⁃α expression in BV2 cells , but did not affect GIV expression ; siRNA interference with GIV gene expression further in creased the expression of inflammatory factors IL⁃6 and TNF⁃α .
Conclusion
The GIV gene may be characteristically involved in regulating the neuroinflammatory response induced by cerebral ischemia⁃reperfusion injury , and it may be a potential therapeutic target for cerebral ischemia⁃reperfusion injury.
5.Spatial distribution and influencing factors among middle-aged and elderly patients with hypertension
Liming TAN ; Lu CHEN ; Mingyan LONG ; Changyan FU ; Lulu ZHOU ; Tiancheng ZHANG
Journal of Preventive Medicine 2019;31(3):236-241
Objective :
To investigate the spatial distribution and the influencing factors of hypertensive patients aged 45 years and above,and to provide evidence for the prevention and control of hypertension among middle-aged and elderly population.
Methods :
Multi-stage stratified random sampling method was used to collect 150 counties(cities or districts)from 30 provinces(municipalities or autonomous regions)from CHARLS database in 2015 according to the per capita GDP in different areas. Then the probability proportionate to size sampling method was used to select three villages(neighborhood committees),80 families were randomly selected from each village(neighborhood committees),and residents aged 45 years and above were interviewed. Spatial analysis was based on the vector map of China's provincial boundaries,Geoda and ArcGIS 10.2 software were used to analyze the prevalence and influencing factors of hypertension at provincial levels.
Results :
The health data of 14 880 people aged 45 years and above in 28 provinces(municipalities or autonomous regions)were obtained,including 4 203 patients with hypertension(28.25%)and 5 408 people with pre-hypertension(36.34%). The results of local spatial analysis showed that the clustering regions of hypertension patients were in northeast and eastern parts of China. The results of spatial regression analysis showed that males,age of 80 years and above and overweight were the main risk factors for hypertension(all P<0.05),which had greater influence on the middle part of China,north and northeast of China,and the east and north of China,respectively.
Conclusion
Males,age of 80 years and above and overweight were the main risk factors for hypertension in middle-aged and elderly population in China. The main prevention and control areas of hypertension were eastern and northeast China.


Result Analysis
Print
Save
E-mail